Abstract |
We investigated the expression of intercellular adhesion molecules ICAM-1 and ICAM-3 on peripheral blood mononuclear cells in a subgroup of 34 patients with relapsing-remitting multiple sclerosis who were treated orally with the chemokine receptor 1 antagonist BX 471 in a 16-week, randomised, double-blind, placebo-controlled phase II study. ICAM-1 and ICAM-3 expression was measured by flow cytometry at different time points during and after therapy and compared using multivariate analysis of variance and non-parametric Mann Whitney test. ICAM-3 expression on CD14( +) peripheral blood mononuclear cells was increased in the verum group under therapy, but did not differ significantly between the verum and placebo groups. Most likely, this trend represents a small epiphenomenon only mediated by receptor cross-talk and feedback mechanisms.
|
Authors | R Reuss, V Schreiber, A Klein, C Infante-Duarte, M Filippi, W Pabst, C Pohl, P Oschmann |
Journal | Multiple sclerosis (Houndmills, Basingstoke, England)
(Mult Scler)
Vol. 16
Issue 3
Pg. 366-9
(Mar 2010)
ISSN: 1477-0970 [Electronic] England |
PMID | 20086017
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigens, CD
- CCR1 protein, human
- Cell Adhesion Molecules
- ICAM3 protein, human
- Immunologic Factors
- Lipopolysaccharide Receptors
- Phenylurea Compounds
- Piperidines
- Receptors, CCR1
- Intercellular Adhesion Molecule-1
- BX 471
|
Topics |
- Administration, Oral
- Antigens, CD
(blood)
- Cell Adhesion Molecules
(blood)
- Double-Blind Method
- Flow Cytometry
- Germany
- Humans
- Immunologic Factors
(administration & dosage)
- Intercellular Adhesion Molecule-1
(blood)
- Italy
- Leukocytes, Mononuclear
(drug effects, immunology)
- Lipopolysaccharide Receptors
(blood)
- Multiple Sclerosis, Relapsing-Remitting
(drug therapy, immunology)
- Phenylurea Compounds
(administration & dosage)
- Piperidines
(administration & dosage)
- Receptors, CCR1
(antagonists & inhibitors)
- Time Factors
- Treatment Outcome
|